DK1267937T3 - Polysaccharide polypeptide conjugate - Google Patents
Polysaccharide polypeptide conjugateInfo
- Publication number
- DK1267937T3 DK1267937T3 DK01914811T DK01914811T DK1267937T3 DK 1267937 T3 DK1267937 T3 DK 1267937T3 DK 01914811 T DK01914811 T DK 01914811T DK 01914811 T DK01914811 T DK 01914811T DK 1267937 T3 DK1267937 T3 DK 1267937T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- polysaccharide
- polypeptide conjugate
- amino group
- free amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention relates to a method for producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide comprising at least one free amino group. A polysaccharide carrier having vicinal hydroxy groups is oxidized onto the polypeptide whereby the ring is opened so as to create vicinal aldehyde groups and is reacted with one or more base-instable antigen polypeptide(s) containing at least one free amino group, the polypeptide(s) being bound directly to the polysaccharide carrier via at least one azomethine bond.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT4712000 | 2000-03-21 | ||
PCT/AT2001/000079 WO2001070272A1 (en) | 2000-03-21 | 2001-03-21 | Polysaccharide-polypeptide conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1267937T3 true DK1267937T3 (en) | 2009-08-03 |
Family
ID=3674758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01914811T DK1267937T3 (en) | 2000-03-21 | 2001-03-21 | Polysaccharide polypeptide conjugate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1267937B1 (en) |
AT (1) | ATE429251T1 (en) |
AU (1) | AU2001242084A1 (en) |
CA (1) | CA2404111C (en) |
DE (1) | DE50114852D1 (en) |
DK (1) | DK1267937T3 (en) |
ES (1) | ES2325528T3 (en) |
MX (1) | MXPA02008247A (en) |
SI (1) | SI1267937T1 (en) |
WO (1) | WO2001070272A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10209821A1 (en) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of proteins to a modified polysaccharide |
AT502293B1 (en) * | 2002-05-15 | 2008-03-15 | Igeneon Krebs Immuntherapie | IMMUNOGENERAL, MONOCLONAL ANTIBODY |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
WO2005044861A1 (en) * | 2003-10-31 | 2005-05-19 | Wyeth Holdings Corporation | Polysaccharides of helicobacter pylori |
CN102302787A (en) * | 2004-03-11 | 2012-01-04 | 费森尤斯卡比德国有限公司 | Conjugates of hydroxyalkyl starch and a protein |
DE102006035899A1 (en) | 2006-07-31 | 2008-02-07 | Dade Behring Marburg Gmbh | New polysaccharide-peptide-conjugate, where the peptide portion contains a sequence having a signal group that is splittable by thrombin at its carbon-terminal end, useful in a procedure for determining the thrombin generation in a sample |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU730694A1 (en) * | 1976-07-05 | 1980-04-30 | Всесоюзный Научно-Исследовательский Технологический Институт Антибиотиков И Ферментов Медицинского Назначения | Terrilitine-modified dextran possessing fibrinolytic activity |
WO1996020012A2 (en) * | 1994-12-23 | 1996-07-04 | Middlesex Sciences, Inc. | Methods for preparing and purifying macromolecular conjugates |
US6011008A (en) * | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
CA2233725A1 (en) * | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
-
2001
- 2001-03-21 MX MXPA02008247A patent/MXPA02008247A/en active IP Right Grant
- 2001-03-21 EP EP01914811A patent/EP1267937B1/en not_active Expired - Lifetime
- 2001-03-21 ES ES01914811T patent/ES2325528T3/en not_active Expired - Lifetime
- 2001-03-21 AT AT01914811T patent/ATE429251T1/en active
- 2001-03-21 WO PCT/AT2001/000079 patent/WO2001070272A1/en active Application Filing
- 2001-03-21 AU AU2001242084A patent/AU2001242084A1/en not_active Abandoned
- 2001-03-21 DK DK01914811T patent/DK1267937T3/en active
- 2001-03-21 DE DE50114852T patent/DE50114852D1/en not_active Expired - Lifetime
- 2001-03-21 CA CA2404111A patent/CA2404111C/en not_active Expired - Fee Related
- 2001-03-21 SI SI200130920T patent/SI1267937T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2404111C (en) | 2010-05-25 |
EP1267937B1 (en) | 2009-04-22 |
ES2325528T3 (en) | 2009-09-08 |
AU2001242084A1 (en) | 2001-10-03 |
DE50114852D1 (en) | 2009-06-04 |
CA2404111A1 (en) | 2002-09-19 |
ATE429251T1 (en) | 2009-05-15 |
MXPA02008247A (en) | 2004-04-05 |
EP1267937A1 (en) | 2003-01-02 |
SI1267937T1 (en) | 2009-10-31 |
WO2001070272A1 (en) | 2001-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE369878T1 (en) | CARRIER-PHARMACY CONJUGATES | |
HUP0402192A2 (en) | Lyophilized preparation containing antibodies to the egf receptor | |
RS54468B1 (en) | Monoclonal antibodies against claudin-18 for treatment of cancer | |
EP2345671B8 (en) | Optimized fc variants and methods for their generation | |
NZ590690A (en) | Antibodies that bind to p-selectin glycoprotein ligand 1 | |
BRPI0410031A (en) | optimized fc variants and methods for their generation | |
TR200200472T2 (en) | Dosages for treatment with anti-Erb B2 antibodies | |
ES547495A0 (en) | PROCEDURE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES TO CYCLOSPORINS. | |
AU2002355677A1 (en) | Antigenic polypeptides | |
AU5055593A (en) | Antibodies specific for HIV | |
ATE354644T1 (en) | CATALYTIC ANTIBODY AGAINST ALDOLASE | |
IL123294A0 (en) | Monoclonal antibody BR110 and uses thereof | |
MXPA04004814A (en) | Methods for ligand discovery. | |
RS50258B (en) | Method for the preparation of citalopram | |
WO1999012971A3 (en) | Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins | |
BR9809656A (en) | Immunopotentiating composition | |
CA2348026A1 (en) | Antibodies against semp1, methods for their production and uses thereof | |
DE50114852D1 (en) | POLYSACCHARIDE POLYPEPTIDE CONJUGATE | |
DE69717490D1 (en) | NON-AGREED FLUORESCENT CONJUGATES AND METHOD FOR THEIR PRODUCTION | |
ATE490271T1 (en) | RECEPTOR, ITS USE AND MOUSE ANTIBODIES | |
SE0002835D0 (en) | Method and kit for production of monoclonal antibodies | |
WO2003016353A1 (en) | Anti-ciguatoxin monoclonal antibody | |
NO20006205L (en) | Morphine-6-glukuronidsyntese | |
PT1064265E (en) | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | |
DE69617255D1 (en) | HLA-B44 MOLECULES PRESENT TUMOR REPELLENT REPELLERS AND THEIR USE |